tularemia

Vaccines
Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity
Katharina Richard, Barbara J. Mann, Aiping Qin, Eileen M. Barry, Robert K. Ernst, Stefanie N. Vogel
VACCINE RESEARCH
Oral Live Vaccine Strain-Induced Protective Immunity against Pulmonary Francisella tularensis Challenge Is Mediated by CD4⁺ T Cells and Antibodies, Including Immunoglobulin A
Heather J. Ray, Yu Cong, Ashlesh K. Murthy, Dale M. Selby, Karl E. Klose, Jeffrey R. Barker, M. Neal Guentzel, Bernard P. Arulanandam
VACCINE RESEARCH
Francisella tularensis Infection-Derived Monoclonal Antibodies Provide Detection, Protection, and Therapy
Anne G. Savitt, Patricio Mena-Taboada, Gloria Monsalve, Jorge L. Benach
VACCINE RESEARCH
Neisseria meningitidis PorB, a Toll-Like Receptor 2 Ligand, Improves the Capacity of Francisella tularensis Lipopolysaccharide To Protect Mice against Experimental Tularemia
Damiana Chiavolini, Susan Weir, John R. Murphy, Lee M. Wetzler
MICROBIAL IMMUNOLOGY
Kinetics of the Immune Response Associated with Tularemia: Comparison of an Enzyme-Linked Immunosorbent Assay, a Tube Agglutination Test, and a Novel Whole-Blood Lymphocyte Stimulation Test
Henrik Eliasson, Per Olcén, Anders Sjöstedt, Margareta Jurstrand, Erik Bäck, Sören Andersson